Wedbush Reiterates Outperform on Nuvalent, Maintains $125 Price Target

Benzinga Newsdesk www.benzinga.com Negative 52.0%

Neg 52% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $125 price target.

Comments

No comments yet. Be the first!